NVP-LDE225 是一种Smo的选择性拮抗剂，能够抑制鼠 Smo (IC50:1.3 nM)和人 Smo (IC50:2.5 nM)。

LDE225 (NVP-LDE225; Erismodegib), a Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively.

PAMPA实验显示,LDE225的渗透性可达90.8%.在临床物种的梯度稀释试验中,LDE225表现出良好的口服药效率,生物药效率为69%-102%.LDE225呈弱碱性（pKa：4.20）,且其水溶性也相对较差.LDE225有剂量依赖性的抗肿瘤活性.LDE225与大鼠,小鼠以及人源的血浆蛋白的结合能力很强(>99%),且可与狗和猴子的血浆蛋白结合,结合能力分别是77%和 85%.在Rip1-Tag2小鼠体内,LDE225可显著减少95.7%的肿瘤体积.LDE225（5 mg/kg/天）显著抑制肿瘤生长,与33%的T/C值相同.LDE225（10或20 mg/kg/天）促使肿瘤退化的效果分别达到51%和83%.Gli1 mRNA抑制性与LDE225介导的肿瘤与血浆接触有关.在肿瘤移植的动物模型中,经过四天的给药处理,LDE225可成功透过血脑屏障抑制肿瘤生长.

LDE 225（0.6-0.8 μM）可抑制TM3荧光报告细胞系（经1 nM-25 nM Hh激动剂Ag1.5 处理）。

LDE225 is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are cultured in F12 Ham's/DMEM (1:1) containing 5% horse serum, 2.5% fetal bovine serum (FBS), and 15 mM HEPES, pH 7.3. Cells are harvested by trypsin treatment, resuspended in F12 Ham's/DMEM (1:1) containing 5% horse serum and 15 mM HEPES, pH 7.3, added to assay plates, and incubated with LDE225 for approximately 30 min at 37 °C in 5% CO2. Then 1 nM or 25 nM Ag1.5 is added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 values, defined as the inflection point of the logistic curve, are determined by nonlinear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of LDE225 using the R statistical software pack (Only for Reference)

956697-53-3

C26H26F3N3O3

485.5

NVP-LDE225;Erismodegib;LDE225

DMSO:90 mg/mL (185.4 mM)
H2O:<1 mgml
Ethanol:90 mg/mL (185.4 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years